Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0SWCOG)
| ADC Name |
ADC2122
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
ADC2122; ZV203; ZV201; ZV0201; HS640; ZV0203; ADC-2122
Click to Show/Hide
|
|||||
| Organization |
Hisun Pharmaceutical (Originator);Zhaohua Biotech;Concortis Biosystems;Accurus Biosciences
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Pertuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Duostatin 5
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Pip-Val-Cit linker
|
Linker Info | ||||
| Conjugate Type |
Reactive Lysines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|